Tokyo-listed biotech company GNI Group said on June 5 that it will acquire all shares of Ayumi Pharmaceutical Holdings from Blackstone and other shareholders for 44.8 billion yen, making the company a wholly owned subsidiary. While headquartered in Japan, GNI…
To read the full story
Related Article
- GNI Targets Above-Industry Growth in Japan after Ayumi Buyout
July 3, 2026
- GNI Closes Acquisition of Ayumi Pharma
July 2, 2026
BUSINESS
- Argenx Steps Up Japan Hunt for Drug Discovery Seeds
October 7, 2026
- 1 in 4 Epilepsy Patients Dissatisfied with Current Drugs: Survey
October 7, 2026
- Fujifilm Adds Linker-Payload Capacity to Build One-Stop ADC CDMO Service
October 7, 2026
- Asahi Kasei Therapeutics Reports Potential Data Breach Affecting 560,000
October 7, 2026
- Toho Files Objection to Court Block on Takeover Defense Move
October 7, 2026
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…





